Welcome to our dedicated page for Ticketplus news (Ticker: TP), a resource for investors and traders seeking the latest updates and insights on Ticketplus stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ticketplus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ticketplus's position in the market.
Ticketplus (NYSE American: TP) priced its initial public offering at $8.00 per share, issuing 1,875,000 ordinary shares for expected gross proceeds of $15 million before fees. The company granted underwriters a 45‑day option to buy up to 281,250 additional shares at the IPO price, less discounts and commissions.
Ticketplus’ ordinary shares are expected to begin trading on NYSE American on August 7, 2026, under the symbol “TP,” with closing anticipated on or about August 10, 2026, subject to customary conditions. Roth Capital Partners, Bancroft Capital and MDB Capital are joint book‑running managers.